Abstract: Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets.

Abstract: The present invention relates to an embolizing emulsion comprising iodinated oil and an aqueous phase comprising a water-soluble contrast agent for use in the treatment of inflammatory hypervascularization associated with a musculoskeletal disorder.

Abstract: Modified monomers of a Shiga toxin B-subunit (STxB) protein including at least one of: an addition of a reactive unnatural amino acid residue at the C-terminal extremity, and/or a substitution with a reactive unnatural amino acid residue at an amino acid position among Asp 3, Lys 8, Glu 10, Tyr 11, Lys 23, Lys 27, Thr 49, Lys 53, His 58, Asn 59, and Arg 69, reference made to the numbering of STxB from Shigella dysenteriae. Also relates to STxB conjugates, and oligomers, in particular pentamers, of these modified STxB proteins and STxB conjugates; as well as to compositions including the same and their use in treatment, vaccination and diagnosis methods.

Abstract: Novel anti-human CD25 antibodies and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or an antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof.

Abstract: Novel anti-human CD25 antibodies or antigen-binding fragments thereof and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or antigen-binding fragment thereof.

Abstract: A method for performing spacetime-constrained oblivious transfer between various laboratories of a first party A and various laboratories of a second party B. The method includes providing the spacetime-constrained oblivious transfer to satisfy various conditions. The method further includes encoding, by the laboratories of the first party A, various messages in a quantum state selected from various non-orthogonal quantum states. The method further includes transmitting, by the laboratories of the first party A, the quantum state to a first laboratory of the second party B. The method further includes applying, by the first laboratory of the second party B, a quantum measurement on the quantum state to obtain a classical measurement outcome. The method further includes transmitting, by the first laboratory of the second party B, the classical measurement outcome to the laboratories of the second party B.

Abstract: This invention relates to a method for diagnosing and/or prognosticating HER2-dependent cancer in a subject, comprising a) measuring the amount of one or more miRNA selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29a-3p, miRNA 29b-3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-3p and miRNA 542-5p in a sample from the subject; b) comparing the amount of one or more miRNA measured in step a) to a reference value; c) finding a deviation or no deviation of the amount of one or more miRNA measured in step a) from the reference value; and d) attributing said finding of deviation or no deviation to a particular diagnosis and/or prognosis of HER2-dependent cancer in the subject.

Abstract: A photoconductive switch for generating or detecting terahertz radiation (TR) is provided. The photoconductive switch may comprise at least a first and a second pair of electrodes (EV, EH, EGR) on a surface (SS) of a photoconductive substrate, wherein the electrodes of the first pair are separated by a first gap comprising at least a plurality of first rectilinear sections (GV) extending along a first direction (x) and the electrodes of the second pairs are separated by a second gap comprising at least a plurality of second sections (GH) extending along a second direction (y), different from the first direction. The photoconductive switch may further comprise a patterned opaque layer (PML) selectively masking portions of the gaps between the electrodes. Methods and devices for generating and detecting terahertz radiation comprising such photoconductive switches are also provided.

Abstract: A wave shaping device which comprises a tunable impedance surface and a controller connected to the surface in order to control its impedance. The shaping device further comprises a transmission module for receiving a pilot signal used to control the impedance of the surface.

Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.

Abstract: An in vitro assay for inducing extracellular trap (ET) formation, including contacting immune cells, in in vitro culture or within a biological sample, with immobilized human polyvalent immunoglobulins; and to uses thereof, in particular in an in vitro method for screening a drug for its ability to modulate ET formation, in an in vitro method for assessing the susceptibility of a subject to ET formation, in an in vitro method for predicting the response of a subject to a modulator of ET formation, and in in vitro method for monitoring the response of a subject to an immunomodulator.

Abstract: The present invention relates to an in vitro method of culturing a segmented filamentous bacterium strain, comprising co-culturing said segmented filamentous bacterium strain with a eukaryotic host cell, wherein the culture is performed at an O2 level inferior to 5% in a rich tissue culture liquid medium containing bacterial medium components including iron. The present invention also relates to methods for genetically modifying a segmented filamentous bacterium strain comprising a step a culturing the strain in vitro.

Abstract: An apparatus for simulating an atonic uterine body after childbirth includes a one-piece part, which includes: a flexible body having the shape of an atonic uterine body after childbirth, the flexible body is bendable by hand so that the flexible body reproduces a haptic behavior of an atonic uterine body after childbirth; and a rigid neck extending the flexible body, the rigid neck surrounding an opening of the part, the rigid neck having a rigidity greater than a rigidity of the flexible body. The part defines an outer surface and an inner surface. The inner surface defines an inner cavity of the part, wherein the inner cavity opens out into the outer surface so as to define the opening.

Abstract: The invention relates to a method of processing data representative of a person’s binocular motricity, the method comprising the following steps: stimulating the binocular motricity of a person by means of a binocular motricity stimulation device (21) configured to specifically stimulate saccades, vergences or a combination of both or of a reading test (22); physical stimuli in 3D real space seen with both eyes naturally (without artifices); acquiring the movement of the right eye (RE) and the left eye (LE) of a person (P) during said stimulation and, if applicable, a stimulation signal from the binocular motor stimulation device; the method comprising the following steps implemented in a processing unit (3); determination from the movement of the left eye (LE) and the right eye (RE), of an effective trajectory (Tr1) of the eyes in response to each stimulation, an effective trajectory corresponding to a saccade and/or a vergence movement of the eyes.

Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.

Abstract: The inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to a method of treating a subject suffering from a cancer comprising a step of administration simultaneously, separately or sequentially to said subject a therapeutically amount of i) a population of derived engineered fetal stem cells carrying cancer associated fetal neo-antigen and ii) a compound selected from a group which activates immune response, as a combined preparation.

Abstract: The present invention relates to methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof. In particular, the present invention relates to a method for performing antisense oligonucleotide-mediated exon skipping in a retina cell of a subject comprising the step of injecting into the vitreous of the subject an amount of the antisense oligonucleotide.

Abstract: A topical composition including erlotinib and a pharmaceutically acceptable excipient for use in the treatment of a keratoderma in a child, preferably a palmoplantar keratoderma (PPK), wherein the composition is topically administered. The composition may further include a penetration enhancer. The treated subject may be younger than three years old. Also, woven or non-woven fabric support including erlotinib and to dressings, patches, gloves and socks having the support useful in the treatment of a PPK.

Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.

Abstract: A method of preparation of a gold electrode, which includes the steps of: a) inkjet printing on a substrate an ink including gold nanoparticles functionalized with a compound Cap of formula (I) HS-A-Polyalkylene glycol (I), wherein A is a bound or an alkyl chain having 1 to 12 carbon atoms and wherein polyalkylene glycol is polyethylene glycol, polypropylene glycol or a mixture thereof; and b) annealing printed ink, wherein the compound Cap has an average molar mass of less than 500 g/mol, preferably an average molar mass of about 200 g/mol. Also, an electrode obtainable by the method of the invention, a sensor including the electrode and the use of the sensor.